







An Exploration of the Relationships among Race, Socioeconomic Variables, and Patient Outcomes in Patients with COVID-19




























PaO ₁	Norm: 75 - 100	mm Hg 🖕	Bilirubin, mg/dL (µmol/L)	<1.2 (<20)	0
				1.2-1.9 (20-32)	+1
FIO ₂ See Evidence for estimating FiO ₂ from oxygen		96		2.0-5.9 (33-101)	+2
flow/delivery rates				6.0-11.9 (102-204)	+3
On mechanical ventilation Including CPAP	No	Yes		≥12.0 (>204)	+4
Platelets, ×10 ^a /µL	>150	0	Mean arterial pressure OR administration of	No hypotension	0
	100-149	+1	vasoactive agents required Listed doses are in units of mcg/kg/min	MAP <70 mmHg	+1
	50-99	+1		DOPamine ≤5 or DOBUTamine (any dose)	+2
	20-49	+3		DOPamine >5, EPINEPHrine s0.1, or norEPINEPHrine s0.1	+3
	<20	+4		DOPamine >15, EPINEPHrine >0.1, or norEPINEPHrine >0.1	+4
Glasgow Coma Scale If on sedatives, estimate assumed GCS off	15	0	Creatinine, mg/dL (µmol/L) (or urine output)	<1.2 (<110)	0
sedatives	13-14	+1		1.2-1.9 (110-170)	+1
	10-12	+2		2.0-3.4 (171-299)	+2
	6-9	+3		3.5-4.9 (300-440) or UOP <500 mL/day	+3
	<6	+4		≥5.0 (>440) or UOP <200 mL/day	+4














	Results		
	Table 1: Descriptive Statistics	of Sample	
		Overall (N=100)	
	Age Mean (SD) Range More Range More Constant Gender Main Soft A score Mean Soft A score Mean Mean Soft A score Mean Mean TOR (Oz. Q3) Survived or not Died Survived or not Died Survived or not Orafail No Orafail No Orafai	62,420 (7,120) 25,000 - 90,000 54,000, 74,200 54,000, 74,200 5,000, 54,000 5,000, 5,000 5,000, 5,000 5,000, 5,000 37 (7,7,0%) 37 (7,7,0%) 37 (7,7,0%) 37 (7,7,0%) 37 (7,0%) 37 (7,0%) 37 (3,0%) 60 (66,0%) 36 (26,0%) 36 (26,0%) 31 (21,0%) 60 (60,0%) 31 (21,0%) 60 (60,0%) 31 (21,0%) 60 (60,0%) 31 (21,0%) 60 (60,0%) 31 (21,0%) 60 (60,0%) 31 (21,0%) 60 (60,0%) 31 (41,0%) 31	
emoryhealthcare.org			EMORY HEALTHCARE

Results (cont'd)							
Table 3: Su	Table 3: Survival - Compare Characteristics						
	Survived						
	Died (N=23)	(N=77)	Total (N=100)	p value			
Age				0.325			
Mean (SD) Range	65.522 (15.500)	61.494 (17.563)	62.420 (17.120)				
Kange Median	34.000 - 90.000 66.000	25.000 - 99.000 61.000	25.000 - 99.000 63.500				
IQR [Q1, Q3]	55.500, 76.000	54.000,70.000	54.000, 74.250				
SOFA score	55.500, /0.000	54.000,/0.000	54.000, /4. 2 50	0.680			
Mean (SD)	6.130 (3.634)	5.688 (3.023)	5.790 (3.160)				
Range	1.000 -13.000	2.000 - 14.000	1.000 - 14.000				
Median	5.000	5.000	5.000				
IQR [Q1, Q3]	3.500, 9.500	3.000, 8.000	3.000, 8.000				
Organ Failure or not			•	< 0.001 ⁵			
Org Fail No	0 (0.0%)	27 (35.1%)	27(27.0%)				
Org Fail Yes	23 (100.0%)	50 (64.9%)	73(73.0%)				
Gender				0.9583			
Male	13 (56.5%)	44 (57.1%)	57 (57.0%)				
Female	10 (43.5%)	33 (42.9%)	43 (43.0%)				
Race: AA vs Caucasian vs Other				0.0684			
AA	16 (69.6%)	44 (57.1%)	60(60.0%)				
Caucasian	2 (8.7%)	24 (31.2%)	26 (26.0%)				
Asian, Hispanic, unknown	5 (21.7%)	9 (11.7%)	14 (14.0%)				
Payer (merge Comm+BC)	. (0/)	0(0()	(0/)	0.454			
Government	4 (17.4%)	8 (10.4%)	12 (12.0%)				
HMO	5 (21.7%)	16 (20.8%)	21 (21.0%)				
Medicare/Medicaid Commercial, BlueCross	14 (60.9%) 0 (0.0%)	46 (59.7%) 7 (9.1%)	60 (60.0%) 7 (7.0%)				
Zip code Vulnerable Yes vs No, Avg,	0(0.0%)	7 (9.1%)	7 (7.0%)	0.5925			
unknown				0.392			
No, Average, unknown	14(60.9%)	42(54.5%)	56 (56.0%)				
Yes	9 (39.1%)	35 (45.5%)	44 (44.0%)				

